14 reports

  • 10.4 JAPAN
  • NIACIN/NICOTINIC ACID SWOT ANALYSIS, 2015

" Fish oil' s mechanism of action is good.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • PRESCRIPTION LANDSCAPE FOR OTHER CLASSES 2015

About Hypercholesterolemia Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C....

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Clinical Trial profile. 1201 Trial Title
  • 5. All the trials included are unique trials.

Lipid Disorders Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Lipid Disorders Global Clinical Trials Review, H2, 2017" provides an overview of Lipid Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Lipid...

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Target
  • Clinical Trial profile. 240 Trial Title

Dyslipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Dyslipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Dyslipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyslipidemia. Report includes an...

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Target

Atherosclerosis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, “Atherosclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Atherosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Atherosclerosis. Report...

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • Target

Arteriosclerosis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Arteriosclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Arteriosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Arteriosclerosis. Report...

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Omega-##-Carboxylic Acids is a complex mixture of concentrated omega-## free fatty acids purified from crude marine fish oil.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • 8.1.1 FORECAST
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014

EZETIMIBE CONTRIBUTED ##% ($##M), LEAVING ABOUT ##. ##% TO THE OMEGA-## FISH OIL DRUGS ($##M).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • NIASPAN (NIACIN EXTENDED-RELEASE) SWOT ANALYSIS, 2014
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GLAXOSMITHKLINE'S DYSLIPIDEMIA PORTFOLIO ASSESSMENT, 2014
  • HIGHLIGHTS GSK'S CURRENT PORTFOLIO OF DYSLIPIDEMIA THERAPEUTICS.

Dyslipidemia - Current and Future Players Summary GlobalData has released its pharma report, “Dyslipidemia - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dyslipidemia Market. The report identifies and analyses the key...

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.